Steven A. Lubitz, MD, MPH
Cardiac arrhythmias are a leading cause of morbidity and sudden death, and collectively constitute a substantial public health problem. We are focused on understanding the mechanisms of arrhythmias, identifying individuals at risk, and intervening to improve health outcomes. Our group comprises a large and collaborative multi-disciplinary team focused on improving cardiovascular health by leveraging human genetics, prediction modeling, and clinical trials. Several areas of active investigation include:
Determining the genetic basis of arrhythmias: Using genotyping and sequencing techniques, we aim to determine genetic factors that underlie atrial fibrillation, bradyarrhythmias, and sudden cardiac arrest. We leverage rare disease collections and large-scale biorepositories to perform genetic discovery.
Identifying individuals at risk for arrhythmias and related morbidity: By curating datasets including electronic health record data and imaging data, we study factors associated with onset of cardiovascular disease. We use a variety of conventional and novel statistical methods to inform risk assessment.
Improving treatment of individuals with or at risk for arrhythmias: We seek to determine whether specific interventions will improve outcomes and efficiency of care delivery. We are examining digital technology, including wearables, in large-scale clinical trials to screen for atrial fibrillation.
Massachusetts General Hospital
Cardiovascular Research Center
Simches Research Building
185 Cambridge Street, 3.188
Boston, MA 02114